Amgen's Imdelltra slashes small cell lung cancer death risk by 58% in major trial
A late-stage trial demonstrated that adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The combination extended median overall survival to 21.1 months, compared to 12.7 months for Imfinzi alone. These results, presented at the European Society for Medical Oncology Congress, suggest a potential shift in standard care for a disease with poor prognosis.